Lipoprotein(a) and Atherosclerotic Cardiovascular Disease : Where Do We Stand?
Lipoprotein(a) [Lp(a)] consists of a low-density lipoprotein-like molecule and an apolipoprotein(a) [apo(a)] particle. Lp(a) has been suggested to be an independent risk factor of atherosclerotic cardiovascular disease (ASCVD). Lp(a) plasma levels are considered to be 70-90% genetically determined through the codominant expression of the LPA gene. Therefore, Lp(a) levels are almost stable during an individual's lifetime. This lifelong stability, together with the difficulties in measuring Lp(a) levels in a standardized manner, may account for the scarcity of available drugs targeting Lp(a). In this review, we synopsize the latest data regarding the structure, metabolism, and factors affecting circulating levels of Lp(a), as well as the laboratory determination measurement of Lp(a), its role in the pathogenesis of ASCVD and thrombosis, and the potential use of various therapeutic agents targeting Lp(a). In particular, we discuss novel agents, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) that are currently being developed and target Lp(a). The promising role of muvalaplin, an oral inhibitor of Lp(a) formation, is then further analyzed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 25(2024), 6 vom: 21. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tsioulos, Georgios [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.03.2024 Date Revised 30.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms25063537 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370320549 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370320549 | ||
| 003 | DE-627 | ||
| 005 | 20240331001852.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms25063537 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM370320549 | ||
| 035 | |a (NLM)38542510 | ||
| 035 | |a (PII)3537 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tsioulos, Georgios |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipoprotein(a) and Atherosclerotic Cardiovascular Disease |b Where Do We Stand? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2024 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Lipoprotein(a) [Lp(a)] consists of a low-density lipoprotein-like molecule and an apolipoprotein(a) [apo(a)] particle. Lp(a) has been suggested to be an independent risk factor of atherosclerotic cardiovascular disease (ASCVD). Lp(a) plasma levels are considered to be 70-90% genetically determined through the codominant expression of the LPA gene. Therefore, Lp(a) levels are almost stable during an individual's lifetime. This lifelong stability, together with the difficulties in measuring Lp(a) levels in a standardized manner, may account for the scarcity of available drugs targeting Lp(a). In this review, we synopsize the latest data regarding the structure, metabolism, and factors affecting circulating levels of Lp(a), as well as the laboratory determination measurement of Lp(a), its role in the pathogenesis of ASCVD and thrombosis, and the potential use of various therapeutic agents targeting Lp(a). In particular, we discuss novel agents, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) that are currently being developed and target Lp(a). The promising role of muvalaplin, an oral inhibitor of Lp(a) formation, is then further analyzed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a antisense oligonucleotides | |
| 650 | 4 | |a atherosclerosis | |
| 650 | 4 | |a cardiovascular disease | |
| 650 | 4 | |a chronic inflammation | |
| 650 | 4 | |a lepodisiran | |
| 650 | 4 | |a lipoprotein(a) | |
| 650 | 4 | |a muvalaplin | |
| 650 | 4 | |a small interfering RNAs | |
| 650 | 7 | |a Lipoprotein(a) |2 NLM | |
| 650 | 7 | |a Apoprotein(a) |2 NLM | |
| 650 | 7 | |a EC 3.4.21.- |2 NLM | |
| 650 | 7 | |a Apolipoproteins A |2 NLM | |
| 700 | 1 | |a Kounatidis, Dimitris |e verfasserin |4 aut | |
| 700 | 1 | |a Vallianou, Natalia G |e verfasserin |4 aut | |
| 700 | 1 | |a Poulaki, Aikaterini |e verfasserin |4 aut | |
| 700 | 1 | |a Kotsi, Evangelia |e verfasserin |4 aut | |
| 700 | 1 | |a Christodoulatos, Gerasimos Socrates |e verfasserin |4 aut | |
| 700 | 1 | |a Tsilingiris, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Karampela, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Skourtis, Alexandros |e verfasserin |4 aut | |
| 700 | 1 | |a Dalamaga, Maria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 25(2024), 6 vom: 21. März |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:6 |g day:21 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms25063537 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 6 |b 21 |c 03 | ||